Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S

As of June 30, 2026, Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.85, indicating elevated leverage, while an interest coverage ratio of 16.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S posted a return on equity (ROE) of 30.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.24, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.75, useful for judging operating efficiency across full business cycles. The company generates approximately 1.05M in revenue per employee across its workforce of 75,421.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.28 indicates how many times Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S recorded 3.90B in income tax expense. That works out to an effective tax rate of 17.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 21.79B, leaving 17.90B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S's stock has gained approximately 25.47% over the past 52 weeks. The 50-day moving average sits at 13.85, while the 200-day moving average is 13.68.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 31.78B, while operating income came in at 24.00B.

As of June 30, 2026, Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S holds 10.91B in cash and equivalents against 69.56B in total debt, resulting in a net debt position of 56.00B. Total book value stands at 58.96B, with working capital of -6.24B providing operational flexibility.

Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S produced 25.84B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novartis AG Shs Sponsored Canadian Depository Receipt Hedged Reg S posted a gross margin of 74.75, reflecting its pricing power and cost economics. The operating margin of 30.18 and net profit margin of 22.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 71.43 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.